Search PubMed⌕ Search

Biomedical subjects

H Laube

Publications and source records attributed to H Laube.

83 records · Page 5Linked to original sources
PubMedDate not supplied

The effect of two new glucosidase inhibitors on blood glucose in healthy volunteers and in type II diabetics.

Two new glucosidase inhibitors (BAY m 1099 and BAY o 1248) were studied in volunteers and type II diabetics under various conditions. In 6 non-diabetic controls BAY m 1099 when given 3 X 50 mg/day caused a marked depression of the post-meal glucose rise. The effect was found to be more marked after breakfast than after lunch or after dinner. In type II diabetics BAY m 1099, when given in a dose of 2 X 25 mg/day over one week, had no significant effect on post-meal glucose or serum insulin levels. BAY o 1248, when given as a single dose of 15 mg in the morning to type II diabetics, induced a significant decrease of post-meal glucose rise (35 mg/dl after breakfast, 25 mg/dl after lunch) when compared to placebo. Although in parallel serum insulin levels were slightly lower, this change was statistically not significant. The drug reduced glycosuria by 50%. Both compounds induced side effects, such as flatulence or diarrhea when given in therapeutically effective amounts, but were tolerable in most cases. On a weight basis BAY o 1248 was found to have greater therapeutic effects than BAY m 1099. Both drugs can be recommended for use in unsatisfactorily controlled type II diabetics. Further studies should concentrate on the critical dosage which may strike a satisfactory balance between effects and side effects.

1-Deoxynojirimycin↗
PubMedDate not supplied

Biologic and immunologic in vivo and in vitro studies with biosynthetic human insulin.

A preliminary study was performed to estimate the effect of biosynthetic human insulin (BHI) produced by the Eli Lilly Company in comparison with purified pork insulin (PPI) from the same manufacturer. Immunologic studies were done using an intradermal skin test with both insulins and in vitro studies binding with sera containing preformed antibodies against bovine and pork insulin. The studies were undertaken in eight healthy volunteers aged 24-31 yr. Insulin was given subcutaneously in an amount of 0.1 U/kg and 3 days later intravenously in an amount of 0.03 U/kg injected slowly over 1 min. Blood glucose, insulin, C-peptide, and growth hormone were measured at different times between 0 and 360 min. It was shown that BHI and PPI behaved similarly in lowering blood glucose, suppressing C-peptide, and increasing growth hormone via hypoglycemic action. After s.c. injection, BHI was found to reach higher serum concentrations after 60 min than PPI. Correspondingly, the blood glucose curve was significantly lower after BHI than after PPI. This difference was not observed after the i.v. application of both forms of insulin.

Adult↗
PubMedDate not supplied

Guar and its effects on metabolic control in type II diabetic subjects.

The effect of guar mini-tablets (5 g t.i.d.) on carbohydrate and lipid metabolism of outpatients with overt diabetes mellitus with glycosuria (is greater than 5 g/24 h) was determined in an open-controlled, randomized, multicenter, crossover study. A 4-wk pretreatment period was followed by a 6-wk treatment period. The treatment period consisted of a 2-wk guar period (treatment period II), which was followed by the wash-out period. The other half of the patients received treatment in the reverse order. Out of 93 patient records, 79 (41 sulfonylurea [SU] and 38 insulin-treated) were suitable for statistical analysis. No relevant weight-reducing effect of guar could be found in both 2-wk treatment periods. At the end of treatment period II, the lowering of the 1-h postprandial values of blood glucose (SU 12%, insulin 10%), cholesterol (SU and insulin 25%) was significant after 2-wk of guar treatment compared with the wash-out period. No clinically relevant changes in the safety laboratory parameters were observed during guar treatment. Side effects were observed in 40 of the 93 patients included in the trial. Treatment had to be discontinued in 11% of the patients due to gastrointestinal side effects. On the basis of our results,guar treatment in combination with sulfonylurea and insulin can be recommended for the improvement of carbohydrate and lipid metabolism.

Clinical Trials as Topic↗